Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Innova Captab Limited (INNOVACAP.NS)
Panchkula, IN
Innova Captab Limited, established in Panchkula, India, in 2005, operates as a comprehensive pharmaceutical enterprise. Its operations encompass the full spectrum of drug development, from research and development and manufacturing to distribution and marketing, serving both domestic and international markets. The company also extends Contract Development and Manufacturing Organization (CDMO) services to other pharmaceutical businesses within India. Furthermore, Innova Captab is actively involved in developing, producing, and supplying a diverse array of generic medications. These formulations address a broad range of therapeutic areas, including anti-infectives (such as cephalosporins and antivirals), gastrointestinal treatments (like proton pump inhibitors and antiemetics), pain and inflammation management (including NSAIDs and analgesics), respiratory and allergy relief, cardiovascular support, antidiabetics, various neurological and psychiatric therapies, and solutions for urological conditions, among numerous other specialized segments. These pharmaceutical offerings are provided in multiple forms, such as tablets, capsules, dry syrups, injectable powders, ointments, and liquid oral preparations. Innova Captab distributes its branded generic products through an extensive network of distributors and pharmacies, in addition to utilizing various online e-commerce pharmacy platforms.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.45% | +4.99% | +28.65% | +31.58% | +22.34% | +24.04% | -1.58% | +64.98% | +64.98% | +64.98% | +64.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+31.1% ★ Q1'26: +42.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+9.9% Q1'26: +28.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+1.9% Q1'26: -2.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+12.1% Q1'26: +12.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.7% ★ Q1'26: +11.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%0.0% ★ Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.41× Q1'26: 1.32× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 2 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|
| Revenue |
12.44B
est: 12.63B (-1.5%)
|
15.88B
15.86B – 15.89B
+25.7% YoY
|
19.25B
19.07B – 19.43B
+21.2% YoY
|
23.79B
23.19B – 24.38B
+23.6% YoY
|
| EBITDA |
1.86B
est: 1.79B (+3.8%)
|
2.25B
2.25B – 2.26B
+25.7% YoY
|
2.73B
2.71B – 2.76B
+21.2% YoY
|
3.38B
3.29B – 3.46B
+23.6% YoY
|
| EBIT |
1.61B
est: 1.58B (+2.1%)
|
1.99B
1.99B – 1.99B
+25.7% YoY
|
2.41B
2.39B – 2.43B
+21.2% YoY
|
2.98B
2.90B – 3.05B
+23.6% YoY
|
| Net Income |
1.28B
est: 1.30B (-1.2%)
|
1.39B
1.38B – 1.40B
+7.3% YoY
|
1.89B
1.88B – 1.89B
+35.5% YoY
|
2.59B
2.48B – 2.63B
+37.0% YoY
|
| SGA |
1.24B
est: 910.35M (+36.6%)
|
1.14B
1.14B – 1.15B
+25.7% YoY
|
1.39B
1.37B – 1.40B
+21.2% YoY
|
1.71B
1.67B – 1.76B
+23.6% YoY
|
| EPS |
22.41
est: 22.40 (+0.0%)
|
24.35
24.20 – 24.50
+8.7% YoY
|
33.00
32.90 – 33.10
+35.5% YoY
|
44.60
43.30 – 45.90
+35.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 64.2K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Manoj Kumar Lohariwala | Executive Chairman | 10M | male |
| Vinay Kumar Lohariwala | MD & Director | 10M | male |
| Lokesh Bhasin | Chief Financial Officer | 7M | male |
| MukeshKumar Siyaram Singh | Deputy Chief Financial Officer | 3M | male |
| Jayant Vasudeo Rao | Whole-time Director | 2M | male |
| Rakhi Makhloga | Company Secretary of Sharon Bio - Medicine Limited | 990.0K | female |
| Neeharika Shukla | Company Secretary & Compliance Officer | 960.0K | female |
| Ayush Kumar Garg | Head of Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INNOVACAP.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
